.
boston cio of the year® orbie® awards
.
the school in yarmouth that year had a low opt-out rate � 2 percent, the superintendent said � so there was a cap on the amount of disruption an illness could cause.
.
.
biohaven: "rimegepant pivotal phase 3 trial results -- conference call."
.
.
."we were fully aware of the fact that our twins would be the first babies in the world to receive this treatment in utero," corinna said.
.